Key Takeaways Illumina will develop KRAS-based companion diagnostics with global pharma partners.ILMN's TSO Comprehensive generates tumor profiles to guide targeted therapy selection.New CDx partnerships expand ILMN's pipeline supporting precision oncology care.Illumina, Inc. (ILMN)  is set to partner with several global pharmaceutical companies to develop companion diagnostics (CDx) enabled on the TruSight Oncology (“TSO”) Comprehensive genomic profiling test. The new CDx partnerships will focus on KRAS al ...